Contact Lens Comfort Relative to Meibomian Gland Status
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01819194|
Recruitment Status : Completed
First Posted : March 27, 2013
Results First Posted : December 9, 2014
Last Update Posted : June 19, 2018
|Condition or disease||Intervention/treatment||Phase|
|Meibomian Gland Dysfunction||Device: senofilcon A||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||64 participants|
|Intervention Model:||Single Group Assignment|
|Primary Purpose:||Supportive Care|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
Experimental: senofilcon A
Acuvvue Oasys with Hydaclear Plus with 38% water.
Device: senofilcon A
- Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE) [ Time Frame: Post 3 days of wear ]CLUE is survey that is used to assess subjective comfort of the test article. The higher the score the better on a range of 0 to 120.
- Meibbomian Gland Dysfunction (MGD)as Measured by MGD Scale [ Time Frame: Post 3 days of wear ]Meibomian Gland Dysfunction (MGD) as measured using the MGD 0 - 11 scale translated into grades 0 to 3 where 0 refers to absence of markers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01819194
|United States, California|
|Fullerton, California, United States, 92831|